Nicolas Hieronimus says weight loss drugs impact L’Oréal skincare sales

L’Oréal CEO Nicolas Hieronimus has highlighted the growing influence of GLP-1 weight loss medications, such as Ozempic and Wegovy, on the global beauty and skincare market. Speaking on the company’s recent performance, Hieronimus noted that these drugs are fundamentally altering beauty consumption patterns as users seek solutions for side effects associated with rapid weight loss, specifically skin sagging and changes in facial appearance. The shift represents a new frontier for the beauty industry as pharmaceutical trends begin to dictate consumer demand in the skincare sector.

Despite the shifting landscape, the world’s largest beauty company reported robust financial health, with sales increasing by 7.7% during the three months ending in September. This growth figure surpassed previous analyst expectations, demonstrating resilience even as the beauty industry observes a significant demographic of GLP-1 users. While these drugs effectively suppress appetite, they often lead to dermatological side effects that drive consumers toward premium topical treatments to maintain skin elasticity and aesthetic appeal.

To capitalize on this emerging trend, L’Oréal is actively developing specialized products through its high-end brands, including SkinCeuticals and Kiehl’s. These offerings are specifically formulated to address "loose skin" and other dermatological concerns often colloquially referred to as "Ozempic face." Additionally, the company has reinforced its position in the aesthetics market through a strategic stake in the dermatology firm Galderma. Research from Galderma has confirmed that a substantial number of patients on weight loss medications notice visible changes in their facial structure, creating a new demand for non-invasive aesthetic solutions.

The strategic pivot underscores L’Oréal’s broader goal of adapting to medical developments that intersect with the beauty sector. By focusing on products that mitigate the side effects of pharmaceutical weight loss, the company aims to sustain its growth momentum and lead a new category of specialized skincare. Hieronimus's observations suggest that the rise of weight loss medications may serve as a catalyst for innovation rather than a threat to traditional beauty consumption.